Related Experiment Video
Updated: Nov 4, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19
Katherine Julian1, Donald Bucher2, Rohit Jain2
1Penn State College of Medicine, Hershey, Pennsylvania, USA kjulian1@pennstatehealth.psu.edu.
Abstract:
We describe the case of a 65-year-old male who presented to an outside hospital for shortness of breath, nausea and vomiting 8 days after testing positive for COVID-19. Initial workup revealed massive bilateral pulmonary emboli and thrombocytopenia. The patient was then admitted to our hospital, received an inferior vena cava filter and initially started on argatroban for autoimmune heparin-induced thrombocytopenia (HIT) prophylaxis. On hospital stay day 6, labs revealed a diagnosis of HIT in the setting of COVID-19. This case highlights the rare occurrence of a patient developing HIT without heparin exposure and in the setting of a novel infectious agent, COVID-19.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Endocarditis II: Clinical Features of Infective Endocarditis
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pericarditis II: Clinical Features and Diagnostic Tests

